The clinical patterns and predictors of cytomegalovirus (CMV) disease in kidney and/or
pancreas transplant patients on ganciclovir (1.0 g po tid) or valganciclovir (450 mg po qd) …

Background. The optimal regimen for prophylaxis of cytomegalovirus (CMV) disease after
kidney and/or pancreas transplantation remains unclear. We compared the effectiveness of …

We investigated retrospectively the risk factors for cytomegalovirus (CMV) infection under
ganciclovir or valganciclovir prophylaxis (oral ganciclovir 1 g tid, valganciclovir 450 mg/d) in …

Background: Optimal prophylaxis against cytomegalovirus (CMV) disease for organ
transplant patients at risk for primary infection (donor seropositive, recipient seronegative …

Background. Despite advances in antiviral therapies, cytomegalovirus (CMV) remains the
leading opportunistic infection in the transplant population. Valganciclovir (VGC), the l‐valyl …

We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in
preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant …

Unlike parenteral gancicovir, the efficacy of oral ganciclovir in the prevention and treatment
of cytomegalovirus (CMV) infection in kidney transplantation has not been well documented …

The natural history of cytomegalovirus (CMV) disease associated with solid organ
transplantation has been modified as a result of the widespread use of antiviral prophylaxis …

Cytomegalovirus (CMV) infection is still the most common opportunistic infection following
solid organ transplantation despite the introduction of newer anti-viral medications for …

Background: Although the primary treatment of symptomatic cytomegalovirus (CMV) disease
in organ transplant recipients is successful in> 90% of individuals, relapsing disease …